ATANIS Biotech raises capital
Oberkirch - ATANIS Biotech AG in the canton of Lucerne has successfully completed a capital increase. With the proceeds, it will accelerate its product development and scale its services for pharma and biotech customers.
ATANIS Biotech AG with headquarters in the canton of Lucerne has announced a capital increase. Founded in 2021, the spin-off from the University of Bern is a biotech specialising in functional allergy diagnostics. In 2022, it won first place in the Stage-Up Competition by the Entrepreneurship Center at the University of Bern.
The capital increase is called “significant” in a press release. No figures are mentioned. The proceeds from the financing will be used to accelerate product development, scale services for pharma and biotech customers and implement the go-to-market strategy.
The round was co-led by the French venture capital fund iXLife together with AllerFund in the USA. The venture capital firm is dedicated to driving social impact for the food allergy community. According to the company, additional investments came from experienced private biotech investors.
The mission of ATANIS is “to revolutionize the way allergies are diagnosed and thereby improve treatment success and quality of life for patients,” said CEO Jean-Pierre Kine. “With this funding, we look forward to taking the next steps towards bringing our products to the market and making them available to clinicians.”
ATANIS is reportedly developing its FAST-PASE technology, offering laboratory testing solutions to mimic allergic reactions safely in a test tube. Currently, the company is mainly serving customers with needs in preclinical drug development and quality control testing. In March, ATANIS moved its operational premises to a new location in Bern enabling the company to increase its sample processing capacity.
